Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In case anyone wasn't aware, NuVec is based on technology from the U of Queensland, who specialise in nano-therapeutics and silica particles.
So while this link has little to do with the NuVec platform, its encouraging another U of Q nanotechnology has been successfully commercialised!
https://advances.sciencemag.org/content/advances/6/22/eaay7148.full.pdf
https://pubs.rsc.org/en/content/articlelanding/2019/ra/c9ra04845f
https://pubs.rsc.org/en/content/articlelanding/2020/tb/d0tb00720j
Both have spherical silica with grown spikes but the manufacturing is different to the UofQ original concept.
These show silica is being formed to replicate Nuvec and this would be down the results seen so far. Silica was replaced with more modern delivery systems when it was easier to change the size, pore size and structures with newer materials. Silica now has been understood more and still carries the original positives such as chemically inactive (no toxicity), also can be mass produced cheaply. The spikes are without doubt the masterpiece of the whole design, it’s the spikes that do the magic with protection and adhesion. The agglomeration results that are due soon will also have more data on the spike behaviour in a more dispersed variant.
Nigel has competently positioned Nuvec within a few pharma sectors, increasing potential and increasing news flow.
Thanks Leister. The nerves are getting to me now. If you could share links that’ll be great - I always read your responses which calms me a lot. I just need to stay positive, calm and patient.
UofQ link has no link at all with Nuvec, the link is for a needleless delivery method that uses a patch to release its cargo (assuming it’ll be a flu vaccine) directly into the skin, great concept for trypanophobia sufferers.
One thing you will all see online more, there’s a very sharp increase in silica nanoparticles being tested again, they did decrease when lipids came along but the structure adaption on silica is now massively improved enough to reignite testing, N4 Pharma have shown great results so it’s natural for others to also try.
I can show links if anyone is interested.
Maybe, they have used some of the data that they were doing for N4P and used it in a another form? I’m just being a little paranoid but this would cause some concerns especially if the patent N4 have done does not cover in NZ? Just a thought?
Clearly no link with N4P looking at our SP action since that news on 1st June.
H
https://www.uq.edu.au/news/article/2020/06/uq-congratulates-vaccine-delivery-spinout-global-deals
Booooom if there's a link
What does this mean for N4P?
Yikes
1 June 2020
A spinout company developing technology based on innovative University of Queensland research has announced two partnerships that could revolutionise the manufacture and delivery of vaccines.
Vaxxas, founded by UQ’s technology transfer company UniQuest in 2011, will partner with global biotechnology company Merck (MSD) and German pharmaceutical manufacturer Harro Höfliger in two separate deals relating to the company’s needle-free vaccine delivery technology.
Merck, a world leader in vaccine development, will access Vaxxas’ HD-MAP technology for the development and manufacture of an undisclosed vaccine.
Merck also retains the option to license the Vaxxas platform for two additional vaccines.
Vaxxas will receive A$18 million (US$12 million) in a combination of equity funding and option fees and is eligible to receive future option, development, and commercial milestone payments.
Vaxxas also announced an alliance with pharmaceutical process engineering and manufacturing company Harro Höfliger to develop a manufacturing line with the potential to produce tens of millions of vaccine-HD-MAP products per week.
Vice Chancellor and President of The University of Queensland Professor Peter Høj said Vaxxas was an excellent example of the translation of UQ’s ground-breaking research at scale.
“With the support of the State and Federal Governments and its investors, the company has grown its base at the Translational Research Institute and is set to build on Australia’s biomanufacturing capabilities, presenting opportunities for export and the creation of high-paying jobs here in Queensland,” Professor Høj said.
“Vaxxas is a very exciting prospect, and I congratulate all involved in the company’s success to date.”
The company’s HD-MAP technology,